GlassScriptPhysician profile
Micala M Socko
NPI 1760267439
$1,126.07
in general payments reported to CMS, 2019-2025
21 companies · $507 in 2025
The $507 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $15.40 · 2024: $603 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $213.13 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $203.05 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $104.44 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $73.76 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $73.38 | 2024 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $68.87 | 2024-2025 | |
| Lundbeck LLC | $47.03 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $43.65 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Xeris Pharmaceuticals, INC. | $39.79 | 2024-2025 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $39.18 | 2024-2025 | Eliquis |
| Pfizer INC. | $32.53 | 2024-2025 | |
| Axsome Therapeutics, INC. | $29.36 | 2024 | Auvelity |
| Ferring Pharmaceuticals INC. | $23.24 | 2024 | Rebyota |
| Organon LLC | $19.61 | 2025 | Nexplanon |
| Otsuka America Pharmaceutical, INC. | $19.39 | 2025 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $18.69 | 2024 | Xyosted |
| Pacira Pharmaceuticals Incorporated | $18.16 | 2024 | Iovera, Zilretta, Exparel |
| Verona Pharma, INC. | $16.10 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $16.00 | 2024 | Vaqta, Gardasil 9, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.63 | 2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $13.08 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Micala Socko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.